Gold prices dip as December rate cut bets wane; economic data in focus
DUBLIN - Goldman Sachs & Co. LLC reported its trading activity in Avadel Pharmaceuticals PLC (NASDAQ:AVPL) shares, according to a disclosure filed Wednesday under Irish Takeover Panel rules.
The filing shows that as of November 6, 2025, Goldman Sachs held a long position of 1,809,256 shares (1.85%) and a short position of 719,655 shares (0.73%) in Avadel’s ordinary shares.
The disclosure details multiple transactions executed on November 6, including purchases of Avadel shares at prices ranging from $18.7950 to $18.8000 per share, and sales at $18.8400 to $18.8450 per share.
Goldman Sachs also reported derivatives transactions, reducing long positions in contracts for difference (CFDs) by 2,408 shares at $18.7648 and 7,444 shares at $18.8409.
The filing indicates Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals in connection with takeover-related matters, though specific details about any potential transaction were not included in the disclosure.
The report was submitted in compliance with Rule 38.5(b) of the Irish Takeover Panel Act, which requires disclosure of dealings by connected exempt principal traders.
According to the statement, Goldman Sachs also executed securities borrowing transactions involving 45,200 shares borrowed and 6,280 shares loaned.
The disclosure was made through a regulatory news service filing as required under Irish takeover regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.